All statements.

Several important factors could cause actual results or events to differ materially from the forward-looking statements that makes Transcept, with including risks related to: the opinion of of the FDA on the adequacy of the NDA for marketing approval of Intermezzo to support; FDA of the additional information provided recently by Transcept and the grant by the FDA and maintenance of exclusivity to Intermezzo under Hatch-Waxman, commercial acceptance of Intermezzo , if approved; unforeseen expenses related to FDA approval, commercialization or the business of Transcept generally, Transcept dependence on third parties for Intermezzo to produce; preservation, maintenance and protection of intellectual property in Intermezzo integrated, and if you try the ability of Transcept receive additional funding its business activities its operations.

A three-montharmaceuticals Announces Expected FDA Extension of Regulatory Review Period for Intermezzo Transcept Pharmaceuticals announced that the U.S. Has Food and Drug Administration informed the company that it should expect receive formal notice of a three-month extension of the period for the New Drug Application for Intermezzo . The Intermezzo NDA had one 30th Prescription Drug User Fee Act date of In July 2009 allocated. Under this revised schedule, Transcept now anticipates action from the FDA on the NDA on or before 31 October 2009.Although women are be HPV HPV at any age, infections at a young Old can be particularly dangerous as they have more time to injury that eventually leads to Crab cancer, she explained.

Dr. Franceschi suggested that these exposure to HPV at a younger age is enter said virus more time for long time sequences of events, – produce the development of cancer development of cancer. .